Avoiding intubation and mechanical ventilation during subcutaneous pump implantation under local anesthesia and conscious analgosedation was feasible in patients with pulmonary arterial hypertension.
In patients with pulmonary arterial hypertension (PAH) receiving background therapy, treatment with sotatercept led to significant reductions in pulmonary vascular resistance.
The association of pulmonary hypertension with an increased risk for kidney failure in older adults with chronic kidney disease is a novel finding.
Riociguat may be a useful option for patients with pulmonary arterial hypertension in whom phosphodiesterase-5 inhibitor treatment is insufficient.
Although the mortality of patients with high-risk pulmonary embolism has decreased over time, the decrease cannot be attributed to improved treatments for pulmonary embolism.
The AstraZeneca vaccine, developed with researchers from Oxford University, has been heavily used in Britain
Patients who are older and have systolic, diastolic, and renal dysfunction may benefit from peri-interventional preload reduction therapy before implantation of larger left atrial devices.
Exercise Doppler echocardiography may provide consistent assessment of right heart function and pulmonary circulation when conducted at expert centers.
In pulmonary arterial hypertension, high plasma levels of hepatic growth factor are associated with the right heart maladaptive phenotype and are incremental to the REVEAL score for the prediction of patient outcomes.
Exercise capacity improved, clinical worsening reduced for patients with pulmonary HTN due to interstitial lung disease.